TYK Medicines, Inc

浙江同源康医药股份有限公司

02410.HK

Clinical-stage biopharmaceutical company developing targeted oncology therapies in China, with 11 drug candidates including TY-9591 in Phase II/III trials for EGFR-mutated non-small cell lung cancer.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Connected or related major customers / suppliers
• Pricing policy and price changes
• Outsourced production (OEM / contract manufacturing)
• Business changes and acquisitions
• Losses and path to profitability
• Cash burn and runway
• Investments and fair-value assets
• Related-party transactions and balances
• Chapter 18A biotech